[Pharmacokinetic monitoring].
Boisdron-Celle
M
M
Laboratoire d'oncopharmacologie, CRLCC Paul-Papin, 49000 Angers.
Boulanger
N
N
Gamelin
E
E
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D015992:Body Mass Index; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000378:metabolism; D004347:Drug Interactions; D016903:Drug Monitoring / Q000379:methods; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D000077146:Irinotecan; D008099:Liver / Q000378:metabolism; D017239:Paclitaxel / Q000008:administration & dosage / Q000493:pharmacokinetics; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics
D000970:Antineoplastic Agents; D005047:Etoposide; D000077146:Irinotecan; D019772:Topotecan; D017239:Paclitaxel; D005472:Fluorouracil; D002166:Camptothecin